Soni Smith MD Fully agree!!! An adequate specimen at the very begining gives a better service to our patients!

Kicking off the MSKCC Lymphoma Symposium with a wonderful comprehensive review of DLBCL by Laurie Sehn #msklymphomacme #msksme

Always great to work with Dr Evens and Dr Love!!

Study S2207 is for people with large B-cell #lymphoma that came back or didn’t respond to previous treatment. It asks if adding either of the drugs tazemetostat or zanubrutinib to usual treatment can help patients. Learn more at SWOG.org/S2207. Or call 1-800-4-CANCER.

Save the date for our annual ASH updates on March 1!!

Congrats to Greg Roloff!

Hear from and connect w other #WomenInOncology in a new series, Navigating Mid-Career Success — don't miss the first session on Tues. 10/24!

Register: brnw.ch/21wDBQQ Hematology & Oncology Women Physicians Group—HOWPG Ishwaria Subbiah, MD MS FASCO Suzanne Cole, MD Soni Smith MD Ariela Marshall MD Ashley Love Sumrall, MD, FACP, FASCO Nathalie Mckenzie, MD MSPH

Don’t miss Part 1 of 3 of our ASCO #WomenInOncology Mid-Career series! Next Tues 10/24!
🥂Mid-career — the perfect time to pause, reflect, and be intentional in your career!
🥂Mid-career — that phase where you’re secure enough with your abilities and potential to not make your…

Beautifully organized and delivered talk by Dr Anand Patel at Binaytara Heme Conte in Nashville!! Anand Patel Binaytara Foundation University of Chicago Hematology/Oncology University of Chicago Hem/Onc Fellows UChicago Leukemia Program has been a GREAT meeting

Only a month away #HemeSummit23 - looking forward to hosting at #MusicCity 🎶 with co-chairs Nitin Jain Soni Smith MD Shaji Kumar Binay Shah, MD, MHA Naveen Pemmaraju, MD

'With so many risk factors identified, it may start to feel like every patient has high risk MM. Soon we may be asking a better question: Who actually has standard-risk disease?”. For ASCO news...Risky Business: The Challenge With Defining High-Risk MM ascopubs.org/doi/10.1200/AD…

Thrilled to contribute to Haematologica’s “Landmarks” series with this brief commentary on an iconic paper. We learn from the past! urldefense.com/v3/__https://h…$

Important work showing us that dogmatic clinical trial eligibility criteria need to be individually re-examined in the interest of inclusivity. Thank you Andrew Hantel for including us.

And 3x as expensive as individual pills

Breakthroughs in medicine won’t be breakthroughs if we don’t think about how to allocate them equitably.

Great work by UChicago Pritzker School of Medicine alum and faculty William F Parker, MD, PhD and University of Chicago Hematology/Oncology alum/faculty Ben Derman 👇🏽

🔗 links to 9/10 published Women In Lymphoma - [email protected] invited manuscripts ICML Conference #HematologicalOncology Francesco Bertoni
womeninlymphoma.org/events-%26-news

The University of Chicago Breast Cancer Program is looking to hire an APP to join our team. If you are interested, pls apply. Oncology experience preferred but not required. uchicago.wd5.myworkdayjobs.com/External/job/C…

See you soon! Great data, and two first-ever (for Best of ASCO) educational sessions. Can’t wait! ASCO

Congratulations!!! Thank you for all the hard work!

Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Update by my colleague Supriya Mohile in Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…